The DOI matches its Crossref record; 107 of the 110 references it cites were found in a registry or an index.
Inactivated poliovirus vaccine: past and present experience
Abstract
Many countries have made use of inactivated poliovirus vaccine (IPV) in their national poliovirus control programs since 1955. Until 1961 IPV was the only vaccine available for the control of poliovirus, but subsequently many countries opted to use the Sabin attenuated poliovirus vaccine (OPV), which was perceived as more effective in preventing intestinal infection and in ensuring community protection by spreading to unvaccinated contacts of vaccinees. Nevertheless, IPV has remained the vaccine of choice in several countries, where experience has shown that it represents a safe and effective option for disease control. IPV limits subsequent infection of the pharynx and intestine in vaccinees, and is able to control circulation of poliovirus in a vaccinated population, providing effective community protection. Furthermore IPV contains only killed virus and cannot cause vaccine-associated paralytic poliomyelitis as OPV sometimes does. This paper reviews the history of the use of IPV, with emphasis on its efficacy and its ability to safely protect communities in which it is used. As the incidence of poliomyelitis declines new control strategies should take account of the knowledge of the use of poliovirus vaccines acquired since 1955.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In northern European countries (France, Netherlands, Sweden, Finland, Iceland), IPV schedules have resulted in the eradication of wild-type polioviruses and protected against large outbreaks of paralytic disease for several decades [28].”
From Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge (2012) · cites this paper as [28]
In the citing paper
“IPV alone has successfully eliminated polio transmission in some Northern European countries (Sweden, Finland, Iceland and the Netherlands).”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [73]
In the citing paper
“Purified inactivated viruses have been traditionally used for vaccine development and such vaccines have been found to be safe and effective for the prevention of diseases caused by viruses like influenza virus and poliovirus (7, 8).”
From Development of an inactivated vaccine candidate for SARS-CoV-2 (2020) · cites this paper as [7]
Citations
Cites
Wimmer, E., Hellen, C. U. T., & Cao, X. (1993) · Annual Review of Genetics · doi:10.1146/annurev.ge.27.120193.002033 · Cited by 554
Evans, D. M. A., Dunn, G., Minor, P. D., Schild, G. C., Cann, A. J., Stanway, G., Almond, J. W., Currey, K., & Maizel, J. V. (1985) · Nature · doi:10.1038/314548a0 · Cited by 440
Ogra, P. L., Karzon, D. T., Righthand, F., & MacGillivray, M. (1968) · New England Journal of Medicine · doi:10.1056/nejm196810242791701 · Cited by 397
Strebel, P. M., Sutter, R. W., Cochi, S. L., Biellik, R. J., Brink, E. W., Kew, O. M., Pallansch, M. A., Orenstein, W. A., & Hinman, A. R. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.2.568 · Cited by 337
Sabin, A. B. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.3.420 · Cited by 281
Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
Onorato, I. M., Modlin, J. F., McBean, A. M., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.1.1 · Cited by 246
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984
Nkowane, B. M. (1987) · JAMA · doi:10.1001/jama.257.10.1335 · Cited by 240
Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93
Oostvogel, P. M., van der Avoort, H. G. A. M., Mulders, M. N., van Loon, A. M., Conyn-van Spaendonck, M. A. E., Rümke, H. C., van Steenis, G., & van Wijngaarden, J. K. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92091-5 · Cited by 220
The molecular biology of poliovaccines
Minor, P. D. (1992) · Journal of General Virology · doi:10.1099/0022-1317-73-12-3065 · Cited by 217
Present Position of Immunization Against Poliomyelitis with Live Virus Vaccines
Sabin, A. B. (1959) · BMJ · doi:10.1136/bmj.1.5123.663 · Cited by 198
Research works printed but not linked: 6
- Cdc, 1986, Poliomyelitis—United States, 1975–1984, Morbid. Mortal. Wkly Rep., 35, 180
- 1979, Epidemiological Notes and Reports: follow-up on poliomyelitis—United States, Canada, Netherlands, Morbid. Mortal. Wkly Rep., 28, 345
- 1993, Epidemiological Notes and Reports: isolation of wild polivirus type 3 among members of a religious community objecting to vaccination—Alberta, Canada, 1993, Morbid. Mortal. Wkly Rep., 42, 337
- 1993, Wild poliovirus isolated in Alberta, 1993, CCDR, 19, 57
- Martin, 1959, Deux ans et demi de vaccination antipoliomyélitique (vaccin Lépine) a l'hopital de l'Institut Pasteur. Résultats immunologiques. Importance de l'injection de rappel, Ann. Inst. Pasteur, 97, 757
- Marine, 1962, Limitation of fecal and pharyngeal poliovirus excretion in salk-vaccinated children, Am. J. Hyg., 76, 173
Cited by
Correlates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
“IPV has been reputed not to provide the same immunity, but as previously reviewed (41, 109), poliovirus replication in”
ResultSelf-citationDevelopment of an inactivated vaccine candidate for SARS-CoV-2
Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
Identification of Formaldehyde-induced Modifications in Proteins
Metz, B., Kersten, G. F. A., Hoogerhout, P., Brugghe, H. F., Timmermans, H. A. M., de Jong, A., Meiring, H., ten Hove, J., Hennink, W. E., Crommelin, D. J. A., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310752200 · Cited by 610
Rossio, J. L., Esser, M. T., Suryanarayana, K., Schneider, D. K., Bess, J. W., Vasquez, G. M., Wiltrout, T. A., Chertova, E., Grimes, M. K., Sattentau, Q., et al. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.7992-8001.1998 · Cited by 419
“Whole inactivated virions have been used successfully as vaccines for numerous viruses (16, 17, 41, 42, 46), but traditional means of viral inactivation can denature virion surface proteins.”
Metadata
- Authors
- Murdin, A. D., Barreto, L., & Plotkin, S.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 1996-06
- Volume
- 14
- Issue
- 8
- Pages
- 735-746
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W2047657297
- Cited by
- 135
- References
- 110
- Citations by year
- 2025: 2 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 17 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 5 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 9 · 2012: 6
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Vaccine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Keywords
- inactivated poliovirus vaccine, oral polio vaccine, vaccine-associated paralytic poliomyelitis, community protection, vaccine efficacy, poliomyelitis incidence
- MeSH terms
- Canada, Europe, Health Policy, Humans, Poliomyelitis, Poliovirus Vaccine, Inactivated, United States, Virulence, Vaccines, Inactivated, Immunization Programs, Immunity, Mucosal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inactivated poliovirus vaccine: past and present experience. https://app.cochat.ai/papers/10.1016/0264-410x(95)00211-i
- The paper
- Murdin, A. D., Barreto, L., & Plotkin, S. (1996). Inactivated poliovirus vaccine: past and present experience. Vaccine. https://doi.org/10.1016/0264-410x(95)00211-i
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.